Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007;3(6):937-45.

Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature

Ramadan A Hammoud  1 , Christopher S Vaccari, Sameer H Nagamia, Bobby V Khan
Affiliations
Free PMC article
Review

Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature

Ramadan A Hammoud et al. Vasc Health Risk Manag. 2007.
Free PMC article

Abstract

Activation of the renin-angiotensin system (RAS) is significant in the pathogenesis of cardiovascular disease and specifically coronary atherosclerosis. There is strong evidence that the RAS has effects on the mechanisms of action of atherosclerosis, including fibrinolytic balance, endothelial function, and plaque stability. Pharmacological inhibition of the renin angiotensin system includes angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and renin inhibitors. These agents have clinical benefits in reducing morbidity and mortality in the management of hypertension. In addition, ACE inhibitors and ARBs have shown to be effective in the management of congestive heart failure and acute myocardial infarction. This review article discusses the biochemical and molecular mechanisms involving the RAS in coronary atherosclerosis as well as the effects of RAS inhibition in clinical studies involving coronary atherosclerosis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. [ALLHAT] The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA. 2002;288:2981–97. - PubMed
    1. Al-Mallah M, Tleyjeh I, Abdel-Latif A, et al. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function. J Am Coll Cardiol. 2006;47:1576–83. - PubMed
    1. Andersen S, Schalkwijk CG, Stehouwer CD, et al. Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy. Diabetes Care. 2000;23:1031–2. - PubMed
    1. Collins R, Peto R, MacMahon S, et al. Blood pressure stroke and coronary heart disease. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990;335:827–38. - PubMed
    1. Cushman DW, Wang FL, Fung WC, et al. Differentiation of angiotensin converting enzyme inhibitors (ACE) by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens. 1989;2:294–306. - PubMed

MeSH terms